Immunome (NASDAQ:IMNM) Rating Lowered to Sell at Wall Street Zen

Immunome (NASDAQ:IMNM) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research note on Friday. Finally, Guggenheim reissued a “buy” rating and set a $25.00 target price on shares of Immunome in a report on Monday, August 25th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.20.

Immunome Trading Down 1.7%

Shares of NASDAQ IMNM opened at $15.24 on Friday. Immunome has a 12-month low of $5.15 and a 12-month high of $17.87. The company has a market cap of $1.33 billion, a PE ratio of -5.17 and a beta of 1.96. The stock has a 50 day simple moving average of $12.83 and a 200-day simple moving average of $10.51.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts forecast that Immunome will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMNM. Assetmark Inc. acquired a new stake in shares of Immunome during the 3rd quarter valued at $39,000. BNP Paribas Financial Markets raised its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Immunome during the first quarter valued at $95,000. Finally, Brighton Jones LLC acquired a new position in shares of Immunome in the 2nd quarter valued at $98,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.